Cutaneous manifestations of Taxol therapy.
Taxol is a novel chemotherapeutic agent that has produced substantial responses in early clinical studies [1]. Taxol has excellent activity in a number of malignancies based on recently completed clinical trials, including a 30% response rate in platinum-refractory ovarian cancer patients [2-5]. We are currently conducting trials of dose-intense taxol with granulocyte colony stimulating factor (G-CSF) support in relapsed or refractory ovarian cancer patients. Such dose intensification produces a major response rate in 50% of patients with this disease [6]. Taxol was supplied in 5 ml ampules (6 mg/ml) in polyethoxylated castor oil (Cremophor EL) 50% and dehydrated alcohol and the dose was diluted in either 0.9% sodium chloride or 5% dextrose at concentrations of 0.6 to 1.2 mg/ml. We have noted 3 patients with previously unreported cutaneous manifestations which we believe are taxol related and also report our overall complication rate with the administration of taxol by peripheral intravenous lines.
Link
C J
CJ
Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Sarosy
G A
GA
Kohn
E C
EC
Christian
M C
MC
Davis
P
P
Adamo
D O
DO
Reed
E
E
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D003877:Dermatitis, Contact / Q000209:etiology*; D004359:Drug Therapy, Combination; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000150:complications; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel